Maxigen BiotechTPE:1783 -1.55%87 ROE % is 22.25% as of Dec. 2025, which is 175% above its 10-year median of 8.08. GuruFocus rates TPE:1783 with a GF Score™ of 87/100 and a GF Value™ of NT$60.99 (Significantly Undervalued). Among 799 Medical Devices & Instruments companies, Maxigen Biotech ranks better than 90.24% on this metric.
ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Maxigen Biotech's annualized net income for the quarter that ended in Dec. 2025 was NT$335.0 Mil. Maxigen Biotech's average Total Stockholders Equity over the quarter that ended in Dec. 2025 was NT$1,505.6 Mil. Therefore, Maxigen Biotech's annualized ROE % for the quarter that ended in Dec. 2025 was 22.25%.
The historical rank and industry rank for Maxigen Biotech's ROE % or its related term are showing as below:
TPE:1783'
s ROE % Range Over the Past 10 Years
Min: -1.52 Med: 8.08 Max: 18.23
Current: 18.23
During the past 13 years, Maxigen Biotech's highest ROE % was 18.23%. The lowest was -1.52%. And the median was 8.08%.
TPE:1783's ROE % is ranked better than 90.24% of 799
companies
in the Medical Devices & Instruments industry
Industry Median: 2.42
vs TPE:1783: 18.23
Maxigen Biotech (TPE:1783) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Dec. 2025) net income data. The Revenue data used here is four times the quarterly (Dec. 2025) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Maxigen Biotech ROE % Related Terms
Maxigen Biotech ROE % Historical Data
* Premium members only.
The historical data trend for Maxigen Biotech's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Maxigen Biotech's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Maxigen Biotech ROE % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Maxigen Biotech's ROE % distribution charts can be found below:
* The bar in red indicates where Maxigen Biotech's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Dec. 2025) net income data.
ROE % is displayed in the 30-year financial page.
Maxigen Biotech (TPE:1783) has a ROE % of 22.25% as of Dec. 2025. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Maxigen Biotech and its competitors. This is 175% above median its historical median of 8.08. According to the industry distribution chart, Maxigen Biotech ranks #78 out of 799 companies in the Medical Devices & Instruments industry, placing it in the top 9.8%.
Is Maxigen Biotech's ROE % too high?
Maxigen Biotech's current ROE % of 22.25% is 175% above median its 10-year median of 8.08. The Medical Devices & Instruments industry median ROE % is 2.42. Maxigen Biotech's value of 22.25% is 819.4% above this industry median. Based on the distribution chart, Maxigen Biotech ranks #78 out of 799 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Maxigen Biotech has a GF Score™ of 87/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Maxigen Biotech's ROE % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Maxigen Biotech ranks #78 out of 799 companies for ROE %. This places Maxigen Biotech in the top 10% of its industry — outperforming the majority of peers. The industry median ROE % is 2.42. Maxigen Biotech's value of 22.25% is 819.4% above this benchmark. While the company's 10-year median is 8.08 vs. the industry median of 2.42, Maxigen Biotech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Medical Devices & Instruments company?
The median ROE % among Medical Devices & Instruments companies is 2.42, based on 799 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Maxigen Biotech's current ROE % of 22.25% is 819.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Maxigen Biotech and its competitors. For the Medical Devices & Instruments industry, the median ROE % is 2.42 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Maxigen Biotech's current ROE % is 22.25%, which is 175% above median its own 10-year median of 8.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Maxigen Biotech stock overvalued right now?
Based on GuruFocus' analysis, Maxigen Biotech (TPE:1783) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$60.99, compared to a current price of NT$38.10 — trading 37.5% below its estimated fair value. The current ROE % is 22.25%, which is 175% above median its 10-year median of 8.08 and 819.4% above the Medical Devices & Instruments industry median of 2.42. Maxigen Biotech's overall GF Score™ is 87/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Maxigen Biotech (TPE:1783), the current ROE % is 22.25% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Maxigen Biotech (TPE:1783) Overvalued in 2026?
Based on GuruFocus' analysis, Maxigen Biotech stock appears to be undervalued.
The current stock price of NT$38.10 is trading 37.5% below its estimated GF Value™ of NT$60.99.
GuruFocus considers Maxigen Biotech to be Significantly Undervalued.
Key valuation signals for TPE:1783:
ROE %: 22.25% (175% above median its 10-year median of 8.08)
GF Value™: NT$60.99 vs. price of NT$38.10 (37.5% below fair value)
Industry Position: 819.4% above the Medical Devices & Instruments median (#78 of 799)
No single metric tells the full story. See the TPE:1783 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Maxigen Biotech Inc is engaged in collagen purification, research and development, production and sales of implantable medical device, and production, manufacturing, wholesale and retail of cosmetics. The group had two reportable segments: the biomedical products segment and consumer products segment. Biomedical products segment is engaged in the manufacturing and sales of collagen and bone materials. The consumer products segment is involved in the manufacturing and sales of beauty care products. Geographically, it operates in Taiwan, America, Europe, Asia, and other countries, with the majority of the revenue deriving from Taiwan.
87GF Score
Get the complete analysis for TPE:1783
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:1783 has been successfully added to your 
